Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease

Haematologica

Volumn 100, Issue 7, 2015, Pages 970-977

  Pidala, Joseph ^a,b   Kim, Jongphil ^a,b   Alsina, Melissa ^a,b   Ayala, Ernesto ^a,b   Betts, Brian C ^a,b   Fernandez, Hugo F ^a,b   Field, Teresa ^a,b   Jim, Heather ^a,b   Kharfan Dabaja, Mohamed A ^a,b   Locke, Frederick L ^a,b   Mishra, Asmita ^a,b   Nishihori, Taiga ^a,b   Ochoa Bayona, Leonel ^a,b   Perez, Lia ^a,b   Riches, Marcie ^a,b   Anasetti, Claudio ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE; METHOTREXATE; PREDNISONE; RAPAMYCIN; TACROLIMUS; ANTINEOPLASTIC ANTIMETABOLITE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE SEVERITY; DRUG DOSE ESCALATION; FAILURE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; ACUTE DISEASE; ALLOTRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; SIBLING; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; SEVERITY OF ILLNESS INDEX; SIBLINGS; SIROLIMUS; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84936150654     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.123588     Document Type: Article

References (46)

1. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graftversus- host disease after marrow transplantation from unrelated donors. Blood. 2000;96(6):2062-2068.
2. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010; 16:937-947.
3. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998; 92:2303-2314.
4. Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs. tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372-1377.
5. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
6. Kornblit B, Maloney DG, Storer BE, et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica. 2014; 99(10):1624-1631.
7. Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011; 118(15):4242-4249.
8. Pidala J, Kim J, Anasetti C, et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011;96(11):1678-1684.
9. Pidala J, Kurland B, Chai X, et al. Patientreported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651-4657.
10. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501-3506.
11. Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011; 17(9):1343-1351.
12. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
13. Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as singleagent, short-course prophylaxis of graftversus- host disease. Blood. 2010; 115(16):3224-3230.
14. Burroughs L, Mielcarek M, Leisenring W, et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versushost disease after nonmyeloablative hematopoietic cell transplantation. Transplantation. 2006;81(6):818-825.
15. Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood. 2001;98(13):3868-3870.
16. Lonnqvist B, Aschan J, Ljungman P, Ringden O. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus- host disease. Br J Haematol. 1990; 74:547-548.
17. Mengarelli A, Iori AP, Romano A, et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica. 2003;88(3):315-323.
18. Ruutu T, Volin L, Elonen E. Low incidence of severe acute and chronic graft-versushost disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids. Transplant Proc. 1988;20(3):491-493.
19. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol. 1999;162(5):2775-2784.
20. Zheng Y, Collins SL, Lutz MA, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol. 2007;178(4):2163-2170.
21. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105(12):4743-4748.
22. Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant. 2007;39(9):537-545.
23. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007; 7(7):1722-1732.
24. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood. 2002;100(3):1084-1087.
25. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005; 5(2):228-236.
26. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007; 178(11):7018-7031.
27. Pidala J, Kim J, Jim H, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012; 97(12):1882-1889.
28. Jim HS, Barata A, Small BJ, Jacobsen PB, Pidala J. Quality of life associated with sirolimus for prevention of graft-versushost disease: results from a randomized trial. Haematologica. 2014;99(3):548-553.
29. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11(8):571-575.
30. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
31. Pidala J, Vogelsang G, Martin P, et al. Overlap subtype of chronic graft-versushost disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 2012;97(3):451-458.
32. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
33. Perkins JB, Kim J, Anasetti C, et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18(7):1099-1107.
34. Inamoto Y, Storer BE, Lee SJ, et al. Failurefree survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013;121(12):2340-2346.
35. Martin PJ, Storer BE, Carpenter PA, et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011; 17(1):124-132.
36. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals Of Statistics 1988;16:1141-1154.
37. Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood. 2014;124(8):1372-1377.
38. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus- host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-1215.
39. Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702-708.
40. Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graftversus- host disease. Leukemia. 2009; 23(1):78-84.
41. Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43(2):149-153.
42. Johnston L, Florek M, Armstrong R, et al. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(4):581-588.
43. Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008;26(35):5767-5774.
44. Armand P. The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial American Society of Hematology Annual Meeting and Exposition. New Orleans, LA; 2013.
45. Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17(10):1528-1536.
46. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graftversus- host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560-565.